Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported a 224% year-over-year increase in total revenue to $64.9 million in Q1 2026 driven by strong sales of Revuforj and Niktimvo. The company highlighted leadership in menin inhibition with revumenib (Revuforj) and continued growth of Niktimvo's collaboration revenue. Syndax anticipates key data releases in 2026 including…